Please assess the completion status of the following clinical trial:

Trial Title: BAX 826 Dose-Escalation Safety Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Previously treated male participants aged 18 to 65 years (inclusive) at the time of screening~2. Diagnosis of severe hemophilia A (Factor VIII level \<1%)~3. Previously treated with FVIII concentrates for ≥150 documented Exposure Days (EDs)~4. Karnofsky performance score of ≥60~5. Human immunodeficiency virus negative (HIV-); or HIV+ with stable disease~6. Hepatitis C virus negative (HCV-); or HCV+ with chronic stable hepatitis as assessed by the investigator~7. Able to understand and have provided written informed consent including signature on an informed consent form (ICF) approved by an ethics committee (EC)~8. Have provided written authorization for use and disclosure of protected health information~9. Agree to abide by the study schedule and to return for the required assessments~10. Willing and able to comply with the requirements of the protocol~Exclusion Criteria:~1. Detectable FVIII inhibitor at screening, with a titer ≥0.6 Bethesda Unit (BU)~2. Documented history of FVIII inhibitors with a titer ≥0.4 BU at any time prior to screening~3. Known clinical hypersensitivity towards mouse or hamster proteins or to polysialic acid (PSA)~4. Scheduled elective surgery during study participation~5. Severe chronic hepatic dysfunction~6. Severe renal impairment~7. Currently receiving, or has recently received (less than 3 months prior to study participation), or is scheduled to receive during the course of the study, other PSA-ylated drugs~8. Have received another investigational drug within 30 days prior to study entry and/or is scheduled to receive additional investigational drug during the course of the study in the context of another investigational drug study~9. Diagnosis of an inherited or acquired hemostatic defect other than hemophilia A~10. Currently receiving, or scheduled to receive during the course of the study, an immune-modulating drug other than antiretroviral chemotherapy~11. Has a clinically significant medical, psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the investigator, would affect the safety or compliance of the participant during the study~12. Is a family member or employee of the investigator

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 - Low dose (Type: EXPERIMENTAL): The study is comprised of 3 dose cohorts and two dose escalation steps \[Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants\]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
- Cohort 2 - Medium dose (Type: EXPERIMENTAL): The study is comprised of 3 dose cohorts and two dose escalation steps \[Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants\]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
- Cohort 3 - High dose (Type: EXPERIMENTAL): The study is comprised of 3 dose cohorts and two dose escalation steps \[Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants\]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete